Timothy Maher follows the lifespan of a new chemical entity from initial discovery, through synthesis, preclinical and clinical testing, to approval, launch and post-marketing surveillance. Maher charts the ups and downs along the way from before a drug is approved, through marketing, and use and beyond; and he answers questions like: What is a "black-box" warning? Who's looking out for your well-being? Should "Fen-Phen" have ever happened? What about Vioxx? This project is supported by a Science Education Partnership Award (SEPA) from the National Center for Research Resources, National Institutes of Health. It does not necessarily represent the official views of NCRR or NIH.
Forum Network
Free online lectures: Explore a world of ideas